Lysyl oxidase, a targetable secreted molecule involved in cancer metastasis

Cancer Research

Volumn 76, Issue 2, 2016, Pages 188-192

  Cox, Thomas R ^a   Gartland, Alison ^b   Erler, Janine T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPIONITRILE; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR; NEUTRALIZING ANTIBODY; PROCOLLAGEN C PROTEINASE; PROTEIN LYSINE 6 OXIDASE; TETRATHIOMOLYBDIC ACID; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CIRCULATING TUMOR CELL; DRUG SCREENING; HUMAN; HYPOXIA; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CELL HYPOXIA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; PROTEIN-LYSINE 6-OXIDASE;

EID: 84958969657     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2306     Document Type: Review

References (32)

1. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438: 820-7.
2. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxiainduced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009;15:35-44.
3. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006;8:1369-75.
4. Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 1991;5:206-10.
5. Smith-Mungo L, Kagan H. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 1998;16:387-98.
6. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 2012;12:540-52.
7. Grau-Bové X, Ruiz-Trillo I, Rodriguez-Pascual F. Origin and evolution of lysyl oxidases. Sci Rep 2015;5:10568.
8. Mäki JM, Räsänen J, Tikkanen H, Sormunen R, Mäkikallio K, Kivirikko KI, et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002;106:2503-9.
9. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139:891-906.
10. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007;26:333-9.
11. Xiao Q, Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron 2012;5:261-73.
12. Cox TR, Rumney RM, Schoof EM, Perryman L, Høye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015;522:106-10.
13. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
14. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3:e47.
15. Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, vande Vijver MJ. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat 2015;150:547-57.
16. Van de Vijver MJ,He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. NEngl J Med 2002;347:1999-2009.
17. Baker AM, Bird D, Lang G, Cox TR, Erler JT. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene 2013;32:1863-8.
18. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013;73:1721-32.
19. Baker AM, Bird D, Welti JC, Gourlaouen M, Lang G, Murray GI, et al. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res 2013;73:583-94.
20. Baker AM, Cox TR, Bird D, Lang G, Murray GI, Sun XF, et al. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. J Natl Cancer Inst 2011;103:407-24.
21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Coleman R, Powles T, Paterson A, Gnant M, Anderson S, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015;386: 1353-61.
22. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J Biol Chem 2003;278:14387-93.
23. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3: 721-32.
24. Gilkes DM, Semenza GL. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol 2013;9:1623-36.
25. Voloshenyuk TG, Landesman ES, Khoutorova E, Hart AD, Gardner JD. Induction of cardiac fibroblast lysyl oxidase by TGF-b1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine 2011;55:90-7.
26. Atsawasuwan P, Mochida Y, Katafuchi M, Kaku M, Fong KS, Csiszar K, et al. Lysyl oxidase binds transforming growth factor-beta and regulates its signaling via amine oxidase activity. J Biol Chem 2008;283: 34229-40.
27. Hong HH, Uzel MI, Duan C, Sheff MC, Trackman PC. Regulation of lysyl oxidase, collagen, and connective tissue growth factor by TGF-beta1 and detection in human gingiva. Lab Invest 1999;79:1655-67.
28. Gacheru SN, Thomas KM, Murray SA, Csiszar K, Smith-Mungo LI, Kagan HM. Transcriptional and post-transcriptional control of lysyl oxidase expression in vascular smooth muscle cells: effects of TGF-beta 1 and serum deprivation. J Cell Biochem 1997;65:395-407.
29. Shanley CJ, Gharaee-Kermani M, Sarkar R,Welling TH, Kriegel A, Ford JW, et al. Transforming growth factor-beta 1 increases lysyl oxidase enzyme activity and mRNA in rat aortic smooth muscle cells. J Vasc Surg 1997;25: 446-52.
30. Gacheru SN, Trackman PC, Shah MA, O'Gara CY, Spacciapoli P, Greenaway FT, et al. Structural and catalytic properties of copper in lysyl oxidase. J Biol Chem 1990;265:19022-7.
31. Li W, Chou IN, Boak A, Kagan HM. Downregulation of lysyl oxidase in cadmium-resistant fibroblasts. Am J Respir Cell Mol Biol [Internet] 1995;13:418-25. Available from: http://www.atsjournals.org/doi/abs/10.1165/ajrcmb.13.4.7546771?url-ver=Z39.88-2003&rfr-id=ori:rid: crossref.org&rfr-dat=cr-pub%3dpubmed.
32. Rucker RB, Romero-Chapman N, Wong T, Lee J, Steinberg FM, McGee C, et al. Modulation of lysyl oxidase by dietary copper in rats. J Nutr 1996;126:51-60.